GMED
Globus Medical, Inc.
GMED has the edge over UNH overall, supported by stronger fundamentals and stronger valuation.
UNH
UnitedHealth Group Incorporated
UNH's outlook is improving, though it still trails on the overall score.
GMED Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
GMED's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
GMED PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $72.30 | — |
| Current | 18x | $72.30 | — |
| Cheap | 26x | $106 | +46% |
| Fair | 41x | $166 | +129% |
| Expensive | 70x | $283 | +291% |
Historical ranges are pointers, not guarantees.
GMED has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
GMED Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect GMED's earnings to grow and its profitability to improve, with its revenue holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
GMED Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.18 | +28% |
| Q3 2026 | $4.05 | +31% |
| Q2 2026 | $3.89 | +50% |
| Q1 2026 | $4.28 | +219% |
| Q4 2025 | $3.92 | +423% |
| Q3 2025 | $3.10 | +349% |
| Q2 2025 | $2.60 | +713% |
| Q1 2025 | $1.34 | +103% |
| Q4 2024 | $0.75 | -37% |
GMED has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
GMED Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $763.7M | -0.7% |
| Q2 2026 | $789.6M | +5.9% |
| Q1 2026 | $759.9M | +27% |
| Q4 2025 | $826.4M | +26% |
| Q3 2025 | $769M | +23% |
| Q2 2025 | $745.3M | +18% |
| Q1 2025 | $598.1M | -1.4% |
| Q4 2024 | $657.3M | +6.6% |
GMED's revenue is growing: $764M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +5.4 points |
| Q2 2026 | 23% | +13 points |
| Q1 2026 | 20% | +3.6 points |
| Q4 2025 | 20% | +11 points |
| Q3 2025 | 18% | +10 points |
| Q2 2025 | 10% | +2.3 points |
| Q1 2025 | 16% | +15 points |
| Q4 2024 | 9.2% | +7.5 points |
GMED has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
GMED Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $224.8M | +5.1% |
| Q2 2026 | $176.6M | +464% |
| Q1 2026 | $162.7M | +15% |
| Q4 2025 | $202.4M | +4.7% |
| Q3 2025 | $213.9M | +32% |
| Q2 2025 | $31.3M | +18% |
| Q1 2025 | $141.2M | +493% |
| Q4 2024 | $193.2M | +136% |
GMED has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
GMED Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -1.4M shares |
| 1 year | +0.5% | +623K shares |
| 3 years | +18% | +20.8M shares |
| 5 years | +30% | +31.6M shares |
| Available history | +33% | +34M shares |
GMED has 136M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $142.9M |
| Q2 2026 | $136.1M |
| Q1 2026 | — |
| Q4 2025 | $45M |
| Q3 2025 | $40M |
| Q2 2025 | $25M |
| Q1 2025 | $190.5M |
| Q4 2024 | $1M |
GMED spent $324M buying back its own shares over the past year, up 26% from the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over GMED on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
GMED Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.6x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
| Q4 2025 | -0.7x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -1.9x | Net Cash |
GMED has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
GMED Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.8 | Neutral |
| Stochastic | 15.8 | Oversold |
GMED's weekly RSI is 42 (neutral) and its Stochastic is 16 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
GMED PE vs Healthcare Sector
| Metric | GMED | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 31% below |
| PE % | 0 | 29 | 29 pts below |
GMED has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
GMED Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $75.5 | 4.3% below |
| 20 week MA | $78.0 | 7.3% below |
| 50 week MA | $83.6 | 14% below |
| 100 week MA | $76.5 | 5.5% below |
| 200 week MA | $68.5 | 5.6% above |
GMED has fallen below most of its moving averages, though it's still 5.6% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over GMED on trend strength, trading above more of its moving averages.
GMED Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.9 | $65.3 | +11% |
| 2021 | $65.3 | $72.2 | +11% |
| 2022 | $72.2 | $73.9 | +2.3% |
| 2023 | $73.9 | $53.3 | -28% |
| 2024 | $53.3 | $83.6 | +57% |
| 2025 | $83.6 | $88.4 | +5.8% |
| 2026 YTD | $88.4 | $72.3 | -18% |
GMED has finished higher in five of the last six years. It's down 18% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over GMED on returns for 2026, with the stronger performance.